Can a Low-Dose opioid curb suicidal urges in depression?

NCT ID NCT04116528

Completed Symptom relief Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking buprenorphine (a low-dose opioid) after a ketamine infusion can reduce suicidal thoughts more quickly and effectively than ketamine alone in people with major depression. Fifty adults participated, and researchers measured changes in suicidal ideation over several weeks. The goal is to find a faster-acting treatment for suicide risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: buprenorphine
What this could lead to: If it works, this could point toward a faster way to reduce suicidal thoughts in people with major depression.
What could go wrong: This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. Buprenorphine is an opioid and carries risks of dependence and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR II DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar II disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

Stanford University School of Medicine

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.